Recruiting PHASE3 Atherosclerosis Cardiovascular Disease

New treatment option for Atherosclerosis Cardiovascular Disease

Official title A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

ClinicalTrials.gov ID: NCT07241390

What this study is testing

What is Orforglipron?

Orforglipron is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for atherosclerosis cardiovascular disease.

Also referred to as LY3502970.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
  • Phase 3: a large, late-stage study
  • You might receive a placebo (an inactive treatment) instead of the study drug.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 50 and older

You may be able to join if

  • Have established ASCVD and/or CKD

You likely can't join if

  • Have type 1 diabetes
  • Have had a major heart condition within 60 days prior to screening
  • Have New York Heart Association Functional Classification Class IV heart failure

The study team makes the final eligibility decision.

Where it's taking place

  • Bahía Blanca, Argentina
  • Buenos Aires, Argentina
  • C.a.b.a., Argentina
  • CABA, Argentina
  • Corrientes, Argentina
  • Córdoba, Argentina
  • Esperanza, Argentina
  • Godoy Cruz, Argentina
  • Granadero Baigorria, Argentina
  • Junín, Argentina
  • Lanus, Argentina
  • Mar del Plata, Argentina
  • Mendoza, Argentina
  • Quilmes, Argentina
  • Ramos Mejía, Argentina
  • Río Cuarto, Argentina
  • Rosario, Argentina
  • S3000epv, Argentina
  • San Isidro, Argentina
  • SAN M. de Tucuman, Argentina

+ 394 more site(s).

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Bahía Blanca, Argentina; Buenos Aires, Argentina; C.a.b.a., Argentina; CABA, Argentina; Corrientes, Argentina; Córdoba, Argentina and 408 more location(s). Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.